



# Market Announcement

14 November 2019

---

## HeraMED Limited (ASX: HMD) – Trading Halt

### Description

The securities of HeraMED Limited ('HMD') will be placed in trading halt at the request of HMD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 18 November 2019 or when the announcement is released to the market.

### Issued by

**Madeleine Green**

Senior Adviser, Listings Compliance (Perth)

For personal use only



14 November 2019

Madeleine Green  
Senior Adviser, Listings Compliance  
ASX Operations  
Level 40 Central Park  
152-158 St George's Terrace  
PERTH WA 6000

Via Email: [tradinghaltsperth@asx.com.au](mailto:tradinghaltsperth@asx.com.au)

Dear Ms Green

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, HeraMED Limited (Company) hereby requests that its securities be placed into an immediate trading halt pending a response to an ASX price and volume query.

The Company requests that trading in its securities be halted until after the expected announcement is made regarding the above or until the market opens on Monday, 18 November 2019, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

A blue ink handwritten signature of Stephen Buckley.

Stephen Buckley  
Company Secretary

For personal use only

**About HeraMED Limited (ASX:HMD):**

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.

For personal use only